Regeneron to Acquire Pharmaceutical Company for $250 Million
Regeneron Pharmaceuticals, Inc. continues to grow its research efforts in immuno-oncology with the announcement on Wednesday of an agreement to acquire Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.
“As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
Checkmate’s lead investigational candidate is vidutolimod, which is administered into a tumor and is believed to induce and expand anti-tumor T cells and induce tumor regression as a monotherapy in patients whose tumors previously progressed on PD-1 checkpoint inhibition.
“The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family,” said Schleifer.
“We are thrilled that Checkmate will become part of Regeneron, a biotechnology leader that shares our deep appreciation for science, hunger for ground-breaking discoveries and commitment to helping patients defeat cancer,” said Alan Bash, President and Chief Executive Officer of Checkmate which is based in Cambridge, Massachusetts.
“We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. It is our hope that Regeneron’s resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy,” said Art Krieg, M.D., Checkmate’s Founder and Chief Scientific Officer.
Similar News Items
What does it take to lead with purpose, grace, and energy — for decades — without burning out? In this inspiring conversation, BCW Member and Balancing Life’s Issues host Wendy Wollner sits down with Dr. Marsha Gordon, President and CEO of The Business Council of Westchester. A trailblazing leader who transformed a struggling local chamber […]
A new collaboration between the Business Council of Westchester (BCW) and Iona University is deploying the innovative power of design thinking to address two community challenges in the Town of Greenburgh. Iona business students will lead the latest City Labs project—a key component of the BCW’s Westchester Innovation Network (WIN). The students will focus on […]
In what was the Business Event of the Year in Westchester County, The Business Council of Westchester (BCW) held its Annual Dinner on October 27 at the VIP Country Club in New Rochelle, celebrating the region’s healthcare excellence with the theme, “Honoring the Legacy of Healthcare in the Hudson Valley.” More than 500 attendees were […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.